Skip to main content

Table 2 Association of miRNA expression with the clinic-pathological features of PCa patients

From: Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients

Clinical features Case no. miR-19a miR-374b
  P   P
Age (years)      
<60 67 4.87 ± 0.62 0.43 3.81 ± 1.19 0.23
≥60 37 4.75 ± 0.97 4.08 ± 1.05
Serum PSA levels (ng/ml) #      
<10 21 4.80 ± 0.66 0.020* 4.00 ± 0.81 0.98
≥10 82 5.16 ± 0.44 4.00 ± 1.17
Gleason score #      
<8 81 4.91 ± 0.44 0.16 3.01 ± 1.571 0.003**
≥8 18 4.68 ± 1.11 4.28 ± 0.692
Clinical stage #      
<T2A 59 4.76 ± 0.65 0.11 3.94 ± 0.146 0.21
≥T2A 41 4.96 ± 0.55 4.21 ± 0.856
Pathological stage #      
T2A-T2C 65 4.82 ± 0.52 0.46 3.64 ± 1.480 0.039*
T3A-T4 35 4.91 ± 0.80 4.21 ± 0.775
Metastasis #      
No 86 4.89 ± 0.49 0.11 4.25 ± 0.076 0.001**
Yes 18 4.57 ± 1.50 2.70 ± 1.661
Overall survival      
Alived 94 4.91 ± 0.55 0.13 4.13 ± 0.096 0.020*
Dead 10 4.04 ± 1.66 2.65 ± 1.655
PSA failure #      
Negative 72 4.88 ± 0.45 0.90 4.31 ± 0.081 0.002**
Positive 27 4.86 ± 0.90 3.36 ± 1.419
  1. #Some patients had missing data for some clinical feature.
  2. * P < 0.05, ** P < 0.01.
\